top of page
Ketamine Academy Blog
Search
FDA Approves Spravato (Esketamine) as Standalone Treatment for Depression
The FDA has approved Spravato (esketamine) nasal spray as the first monotherapy for treatment-resistant depression (TRD)
Jason A. Duprat MBA, MSA, APRN, CRNA
Mar 42 min read
Ketamine’s Cognitive Side Effects: Fact or Myth?
Its reputation as a club drug has raised red flags, but studies show that its effects on cognitive function are dose-dependent.
Ketamine Academy
Oct 13, 20217 min read
Perks, Planning, and People: Things Hindering Off-Patent Ketamine’s FDA Approval for Depression
Unlike esketamine nasal spray, the old formulation doesn’t have FDA approval for treating major depression & similar mental health problems.
Ketamine Academy
Sep 9, 20218 min read
Racemic Ketamine vs. Esketamine: What Is the Difference, and Why Is It Critical to Patient Care?
A quick guide on the chemical, clinical & pharmacological differences between intravenous racemic ketamine & intranasal ketamine.
Ketamine Academy
Aug 4, 20218 min read
bottom of page